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The eight genotypes of hepatitis B virus (HBV) have different geographical distributions, virological char-
acteristics, and clinical manifestations. A unique subtype of HBV genotype A (HBV/A) was reported in
sub-Saharan Africa, raising the possibility that patients infected with this subtype (HBV/Aa [“a” for African
and Asian]) may have different clinical outcomes than other HBV/A isolates (HBV/Ae [“e” for European]).
Comparison between 30 HBV/Aa and 30 HBV/Ae isolates indicated that almost all HBV/Ae isolates had G at
nucleotide (nt) 1809 and C at nt 1812, whereas HBV/Aa isolates had T1809/T1812. Taking advantage of these
two single nucleotide polymorphisms (SNPs), a novel subtype-specific PCR assay in the X/precore/core region
was developed. This assay was combined with a restriction fragment length polymorphism assay using BglII
in a different region (nt 1984 to 1989), which has a SNP distinguishing HBV/Aa from HBV/Ae, resulting in 100%
specificity for the combined assay. Application of the subtyping assay using sera from 109 paid donors in the
United States indicated significantly different distributions of HBV/A subtypes among races; African-Ameri-
cans, Caucasians, and Hispanics had HBV/Ae, whereas Asians had mainly HBV/Aa, suggesting that the
HBV/Aa isolates may have been imported by recent immigration from Asia. In conclusion, the specificity and
sensitivity of the combined subtyping assay were confirmed, and its usefulness was demonstrated in a practical
context.
Hepatitis B virus (HBV) is one of the most important causes
of acute and chronic liver disease, such as fulminant hepatitis,
cirrhosis, and hepatocellular carcinoma, throughout the world,
especially in Asian and African countries. Eight genotypes of
HBV, classified A to H (HBV/A to HBV/H), are distinguished
by intergenotypic differences of more than 8% in the entire
nucleotide sequence of approximately 3,200 nucleotides (nt)
(3, 21, 22, 25). These genotypes have different geographical
distributions, virological characteristics, and clinical manifes-
tations (18, 20). Moreover, among the HBV isolates of the
same genotype, there might also be differences of virological
characteristics.
Recently, in Asian countries, two subtypes of HBV genotype
B, designated Ba (“a” standing for Asia) and Bj (“j” for Japan)
have been reported (27), and clinical differences between pa-
tients infected with HBV/Ba and HBV/Bj are being recognized
(2, 28).
Similarly, a subtype of genotype A was reported and desig-
nated A in sub-Saharan African countries (5). A large number
of HBV isolates from South Africa were found to cluster with
this subtype A by phylogenetic analyses of both the pre-S2/S
region (5) and the complete genome (13, 16). This subtype has
also been found in HBV isolates from Malawi (29). In African
countries, genotype A isolates, most of which are subtype A,
seem to be associated with low levels of HBV DNA in serum
and a low prevalence of hepatitis B e antigen (HBeAg) in
serum (14, 15). On the other hand, HBV carriers infected with
isolates belonging to the remainder of genotype A, distributed
widely in European countries and the United States, have a
higher rate of sustained remission after seroconversion and a
lower rate of death related to liver disease than other geno-
types during long-term follow-up (8, 24, 33).
In this paper, we report a convenient assay with a subtype-
specific PCR combined with a restriction fragment length poly-
morphism (RFLP) assay to distinguish these two subtypes of
genotype A. Recently, a cross-sectional study in the United
States showed a correlation of HBV genotypes not only with
ethnicity but also with the place of birth of the carriers of the
virus (6). By using the newly developed assay, we also exam-
ined the association between the subtypes of HBV/A and eth-
nicity in the United States. To avoid confusion, as previously
proposed (30), the subgroup (subtype) A, which was proposed
by Bowyer et al. (5), is renamed subtype HBV/Aa (“a” stand-
ing for African and Asian), the other subtype found in Euro-
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pean countries and the United States is HBV/Ae (“e” for
European and U.S. type), and genotype A (HBV/A) includes
both HBV/Ae and HBV/Aa.
MATERIALS AND METHODS
Serum samples. Forty HBV/A-positive serum samples were collected from
carriers in four countries (10 each from Japan, the United States, India, and
South Africa) and were used to examine the specificity and sensitivity of our
HBV/A subtype-specific PCR combined with RFLP assay. These serum samples
were stored at 80°C until assayed.
For the practical testing of this assay, 333 sera from HBsAg-positive paid
donors in the United States recruited by ProMedDx Inc. (Plainville, Mass.) were
used in this study. Of the 333 samples, 139 belonged to HBV/A. After hepatitis
C virus- and/or human immunodeficiency virus-infected samples and samples
whose ethnicity was unknown were omitted, 109 samples obtained from 38
African-American, 16 Asian, 24 Caucasian, and 31 Hispanic subjects were ex-
amined. All of them had not received current antiviral therapy, and their alanine
aminotransferase (ALT) levels in serum were normal. For controls, 32 HBV/A
isolates from South African black asymptomatic carriers of HBV with normal
ALT levels were used (age range, 18 to 44 years; 30 [94%] carriers were male).
The study protocol was approved by ethics committees of the institutions, in
accordance with the 1975 Declaration in Helsinki, and an informed consent was
obtained from each subject.
Serological determination of HBeAg and HBV genotypes. HBeAg was de-
tected by the chemiluminescent enzyme immunoassay (Ortho Clinical Diagnos-
tics, Tokyo, Japan). The genotype of these samples was serologically confirmed
as HBV/A by using commercial kits (HBV Genotypes EIA; Institute of Immu-
nology) based on five monoclonal antibodies directed to the corresponding
epitopes on the product of the pre-S2 region which are designated b, m, k, s, and
u (31, 32).
Detection of HBV DNA and cloning. DNA was extracted from 100 l of serum
using a QIAamp DNA blood mini kit (QIAGEN Inc., Hilden, Germany). HBV
DNA of X and precore/core genome sequences were amplified by a method
reported previously (26). In brief, the first-round hemi-nested PCR was per-
formed with sense primer HB7F (5-GAG ACC ACC GTG AAC GCC CA-3 [nt
1611 to 1630]) and antisense primer HB8R-2 (5-ATA GGG GCA TTG GTC
T-3 [nt 2314 to 2299]; a modification of HB8R) for 5 min at 96°C, followed by
denaturation for 1 min at 94°C, annealing for 1 min at 60°C, and extension for 1
min at 72°C (an additional 5 min in the last cycle), in a 96-well cycler (GeneAmp
FIG. 1. Alignment of 40 HBV/A isolates sequenced in the present study with 20 reference isolates. (A) Alignment of sequences of HBV/A
isolates within the subtype-specific region of the primer (nt 1777 to 1836). The positions of sense primers for the second-round PCR are shown
by the arrows above alignments and are shaded in grey. (B) Alignment of sequences of HBV/A isolates within the core region containing a BglII
restriction site (nt 1970 to 2009). The position of the enzyme restriction site is shaded in grey. The isolates sequenced in the present study are
shaded in light grey.
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9600; Perkin-Elmer Cetus, Norwalk, Calif). The second-round PCR was per-
formed with the sense primer HB7F and antisense primer HB7R-2 (5-CCT
GAG TGC TGT ATG GTG AGG-3 [nt 2072 to 2052]; a modification of HB7R)
under the same conditions as the first-round PCR. The amplicons were analyzed
by electrophoresis on 3% agarose gels, stained with ethidium bromide, and
observed under UV light.
To confirm the specificity of the amplification, PCR products were directly
sequenced with Prism Big Dye (Applied Biosystems, Foster City, Calif.) in the
ABI 3100 DNA automated sequencer. For positive controls of HBV/Aa and
HBV/Ae isolates, the second-round PCR products were cloned into TOPO TA
cloning vector (InVitrogen Corp., Carlsbad, Calif.). Plasmids were amplified in
Escherichia coli DH5 cells (TaKaRa Shuzo Co. Ltd., Tokyo, Japan) and purified
by the QIAGEN procedure.
Molecular evolutionary analyses. A phylogenetic tree was constructed to dis-
tinguish the HBV/A subtypes. An alignment of 421 nt (nt 1631 to 2051) of the 40
isolates amplified in this study, together with 24 sequences of HBV/A to HBV/H
isolates obtained from DDBJ, EMBL, and GenBank DNA databases, was ana-
lyzed. By using the computer program Hepatitis Virus Database Server (http:
//s2as02.genes.nig.ac.jp/), the number of nucleotide substitutions per site and the
genetic distances between the isolates were estimated by the six-parameter
method (11), and a neighbor-joining tree was constructed based on these values
(23). To confirm the reliability of the phylogenetic tree, bootstrap resampling
tests were performed 1,000 times (10).
HBV/A subtype-specific PCR combined with RFLP assay. A novel HBV/A
subtyping assay, based on HBV/A subtype-specific PCR combined with a RFLP
assay, was developed and applied to HBV/A isolates only, after the genotype had
been determined serologically using HBV Genotypes EIA. The first-round hemi-
nested PCR was performed with the sense primer HB7F and the antisense
primer HB7R-2 for 5 min at 96°C, consisting of denaturation for 1 min at 94°C,
annealing for 1 min at 60°C, and extension for 1 min at 72°C (additional 5 min
in the last cycle), in a 96-well cycler. The second-round PCR consisted of one of
two sets of primers: set I, HBV/A confirmation PCR using the sense primer
HBxA (5-ATA AAT TGG TCT GCG CAC CA-3 [nt 1789 to 1808]) within
conserved X regions (Fig. 1A) and the antisense primer HB7R-2 (for 5 min at
96°C, consisting of denaturation for 45 second at 94°C, annealing for 45 second
at 62°C, and extension for 45 second at 72°C [additional 5 min in the last cycle]);
and set II, HBV/Ae-specific PCR using the sense primer HBxAe (5-ATT GGT
CTG CGC ACC AGG AC-3 [nt 1793 to 1812]) with the specific sequences for
HBV/Ae at the 3 end (Fig. 1A) and the antisense primer HB7R-2 under the
same conditions as the second-round PCR in set I. In order to distinguish some
unusual isolates and take advantage of another subtype-specific restriction site
(Fig. 1B), the PCR assay was combined with a RFLP assay using BglII. Restric-
FIG. 2. A phylogenetic tree constructed using HBV X/precore/core sequences (nt 1631 to 2051). Isolates sequenced in the present study from
four countries are shown in bold italic. Accession numbers: AB163781 to AB163790 (USA), AB163791 to AB163800 (Japan), AB163801 to
AB163810 (India), and AB163811 to AB163820 (South Africa). Ten HBV/Ae and six HBV/Aa reference isolates obtained from the databases are
labeled with corresponding accession numbers and countries of origin in parentheses. For the other genotypes (HBV/Ba, HBV/Bj, HBV/C,
HBV/D, HBV/E, HBV/F, HBV/G, and HBV/H), reference isolates are also shown by accession numbers. The length of the horizontal bar indicates
the number of nucleotide substitutions per site. The numbers on the nodes indicate the percentage of occurrences by bootstrap analysis.
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tion digestions were carried out using 5 l of the 282-bp amplicon from set II,
with 10 U of restriction enzyme BglII (New England BioLabs, Beverly, Mass.) for
3 h. The digested PCR products were electrophoresed on 3% agarose gels and
stained with ethidium bromide. The RFLP pattern was examined under UV
light; HBV/Ae amplicons were digested into two fragments (221 plus 61 bp),
whereas HBV/Aa amplicons were not restricted.
Statistical analyses. Statistical differences were evaluated by Mann-Whitney U
test, Fisher’s exact probability test, and chi-square test with Yates’ correction,
where appropriate, with use of STATA software version 8.0 (StataCorp. LP,
College Station, Tex.). Differences were considered significant for P values less
than 0.05.
Nucleotide sequence accession numbers. Isolates sequenced in this study were
submitted to the GenBank/DDBJ/EMBL/ databases under the following acces-
sion numbers: AB163781 to AB163790 (USA), AB163791 to AB163800 (Japan),
AB163801 to AB163810 (India), and AB163811 to AB163820 (South Africa).
RESULTS
Molecular evolutionary analyses of HBV/A. Based on the
alignment of 40 isolates from four countries and 24 reference
sequences including HBV/A to HBV/H sequences from the
DDBJ, EMBL, and GenBank DNA databases, a phylogenetic
tree was constructed for the HBV X/precore/core region (Fig.
2). All 20 HBV/A isolates from the United States and Japan
were confirmed to be HBV/Ae, and all 20 isolates from India
and South Africa were classified into HBV/Aa with high boot-
strap values.
Alignment of HBV/A isolates. Figure 1 shows the alignment
of 60 HBV/A sequences (56 sequences from the sequences
used for phylogenetic analysis above and 4 additional short
sequences from Gambia or India), within the subtype-specific
region of the primer (Fig. 1A) and within the core region
corresponding to the BglII RFLP site (Fig. 1B). Almost all
HBV/Ae isolates had G at nt 1809 and C at nt 1812 (G1809/
C1812 pattern), whereas HBV/Aa isolates had T1809/T1812.
Taking advantage of these two single nucleotide polymor-
phisms, two sense primers were designed to distinguish
HBV/Ae from HBV/Aa, and two sets of hemi-nested PCRs
were developed. Examining available sequences from the da-
tabases, we noted exceptions. A few HBV/Aa isolates had
G1809/C1812, and therefore may initially be classified as HBV/
Ae. In order to distinguish these unusual isolates, a RFLP
assay using BglII was developed in a different region of the
HBV genome that contains a single nucleotide polymorphism
distinguishing HBV/Aa and HBV/Ae. Because the restriction
enzyme, BglII, recognizes the nucleotide sequence A/GATCT
(nt 1984 to 1989) (Fig. 1B), HBV/Ae isolates were restricted to
221-plus-61-bp fragments and HBV/Aa isolates were not
(282-bp fragment). Furthermore, some atypical isolates of
HBV/Aa with A1984 were found in the databases; however,
these would be excluded initially by the PCR step because of
the nucleotide pattern (T1809 or A1809/T1812) (Fig. 1A).
Sensitivity of HBV/A subtype-specific PCR combined with
RFLP assay. The sensitivity of the newly developed PCR assay
to distinguish HBV/Ae from HBV/Aa was evaluated on serial
10-fold dilutions containing known copy numbers of both
HBV/Ae and HBV/Aa clones (Fig. 3). As shown in Fig. 3A, the
subtype-specific PCR with sense primer HBxAe could detect
102 copies per ml of the isolates which have G1809/C1812, and
HBV/Aa isolates with T1809/T1812 were not amplified. On the
other hand, the PCR with primer HBxA could detect both
HBV/Ae and HBV/Aa, and the detection limits were 102 cop-
ies per ml (Fig. 3B).
Strategy for the subtyping assay of HBV/A based on HBV/A
subtype-specific PCR combined with RFLP assay. Figure 4A
shows the final strategy of the subtyping assay of HBV/A based
on subtype-specific PCR followed by a RFLP assay. The hemi-
nested PCR assay consisted of two sets of second-round PCR,
with either sense primer HBxAe (named the HBV/Ae-specific
primer) or sense primer HBxA (named the HBV/A confirma-
tion primer), combined with a RFLP assay using BglII, and
allowed HBV/Aa to be clearly distinguished from HBV/Ae. In
brief, when HBV/A isolates were detected by using both sets of
PCR primers and the amplicons were not restricted by the
RFLP step (Fig. 4B), the isolates were classified as HBV/Aa.
On the other hand, when HBV/A isolates were detected by
both sets of PCR primers and the amplicons restricted by
BglII, the isolates belonged to HBV/Ae. The isolates positive
for the PCR with primer HBxA only and not primer HBxAe
were also recognized as HBV/Aa (Fig. 4B).
Application of the HBV/A subtyping assay to U.S. samples.
In order to confirm the practical usefulness of this assay, HBV
isolates from sera of 109 paid donors from the United States,
which had been shown to be HBV/A by enzyme-linked immu-
nosorbent assay, were examined using the subtyping assay. Of
the 109 samples obtained from 38 African-American, 16 Asian,
24 Caucasian, and 31 Hispanic subjects, 79 were classified as
HBV/Ae and 30 as HBV/Aa. There were no differences be-
tween the ethnic groups in the age, gender, and ALT levels in
serum of the donors (Table 1). Interestingly, the prevalence of
HBeAg in the Asian group tended to be lower than that of the
other groups. By examining the ratio of HBV/A subtypes
among isolates from each ethnic group with our new assay,
FIG. 3. Sensitivity of subtype-specific PCR assay. Serial 10-fold di-
lutions containing known numbers of HBV copies of HBV/Ae and
HBV/Aa were tested using HBxAe-specific primer (A) and HBxA
confirmation primer (B). Molecular weight markers are on the right
and/or left lanes.
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84.2% of African-American, 83.3% of Caucasian, and 74.2%
of Hispanic isolates were classified as HBV/Ae, whereas 75%
of the Asian isolates were HBV/Aa. This indicates that the
prevalence of HBV/Aa was significantly higher in Asian iso-
lates than in the other groups (Fig. 5A). As a control study, the
subtyping assay was applied to 32 HBV/A sera from South
Africa, where subtype Aa is known to predominate (5, 13, 16).
A total of 96.9% of HBV isolates belonged to HBV/Aa (Fig.
5B), which was different than the prevalence of HBV/Aa
among African-American donors from the United States.
Moreover, when the HBeAg positivity of subjects younger than
40 was evaluated, we found that the proportion of carriers
infected with HBV/Aa that were positive was lower than with
those infected with HBV/Ae (data not shown).
FIG. 4. (A) The strategy of novel subtyping assay of HBV/A based on subtype-specific PCR combined with RFLP assay with BglII.
(B) Ethidium bromide-strained 3% agarose gel showing the restriction patterns obtained by BglII digestion. HBV/Ae isolates were restricted to
a 221-plus-61-bp fragment and HBV/Aa isolates were not (282-bp fragment). ND, not determined.
TABLE 1. Clinical backgrounds of blood donors from the United Statesa
Ethnicity (n) Mean age, (yr) Male sex (%) ALT median(IU/liter) ALT range (IU/liter) HBeAg positive (%)
African-American (38) 34.2  11.4 19 (50.0) 15 6–22 6/33b (18.2)
Asian (16) 39.3  17.1 12 (75.0) 22 19–40 2/13b (15.4)
Caucasian (24) 40.3  16.3 15 (62.5) 14 6–40 6/24 (25.0)
Hispanic (31) 38.7  14.4 19 (61.2) 18 4–38 5/31 (16.1)
a P values were not significant for any data.
b Five samples in the African-American group and three samples in the Asian group were not available.
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DISCUSSION
In this study, a subtype-specific PCR combined with a RFLP
assay was developed. For HBV/A isolates tested in this study
and data extrapolated from sequences in the database, the
specificity of this new assay in the X/precore/core overlapping
region was 100% and could clearly distinguish HBV/Ae from
HBV/Aa.
In previous studies, when HBV isolates showing intergeno-
typic recombination were excluded, subtype A (HBV/Aa) was
clearly distinguished by phylogenetic analyses from the remain-
ing genotype A (HBV/Ae) in each of the open reading frames
except for the small S region (29, 30). Examining all available
full HBV sequences from the databases, nucleotide sequences
that could distinguish HBV/Aa from HBV/Ae were found in
the X/precore/core region. Notably, T1809/T1812 is a nucleo-
tide pattern very specific for HBV/Aa, and almost all HBV/Ae
isolates and isolates belonging to the other genotypes have
G1809/C1812. Thus, the region of the genome that includes nt
1809 and 1812 was suitable for the subtyping of HBV/A.
In early studies, the individuals infected with HBV in Africa
were shown to very frequently seroconvert from HBeAg pos-
itivity to negativity in childhood or early adulthood (4, 7),
compared with those in the other countries where HBV is
endemic (9, 17, 19). Furthermore, HBV-related virus markers
were frequently found in young patients with hepatocellular
carcinoma in South Africa (12). The unique subtype of
HBV/A (HBV/Aa) was first reported by Bowyer et al. in 1997
(5) and is known to be the major genotype of HBV in South
Africa (16). Taken together, these observations allude to
HBV/Aa isolates in Africa being different than HBV/Ae iso-
lates in western countries. Therefore, it is useful to distinguish
the HBV/Aa with possible different clinical characteristics
from the HBV/Ae on the basis of the unique sequences in the
X/precore/core region.
Of the 40 original isolates from four countries where HBV is
endemic (Japan, the United States, India, and South Africa)
and the 28 reference isolates from the database, just one un-
usual exceptional isolate was found (AF418684 in Fig. 1A).
This isolate clustered with subtype HBV/Aa following a phy-
logenetic analysis but was found to have the characteristics of
HBV/Ae according to the subtype-specific PCR assay. When a
total of 132 available HBV/Aa sequences deposited in the
databases and from our unpublished data (India and South
Africa) were investigated in order to determine the frequency
of isolates that were exceptions, 14 isolates (10.6%) from
South Africa and India (five isolates from South Africa [acces-
sion numbers AF297621, AF297622, AF297623, U87742, and
U87746] and nine isolates from India [accession numbers
AF418684, AF418685, AF418686, AF418687, AF418688,
AF418689, AF418690, AF418691, and AF418692]) had the
G1809/C1812 pattern, and therefore could not be distin-
guished from HBV/Ae isolates by using the subtype-specific
PCR step. However, because these unusual isolates had G
instead of A at position 1984, they were not restricted by BglII
and could therefore be correctly classified as HBV/Aa. On the
other hand, 22 HBV/Aa isolates (16.7%) from Gambia and
India (19 isolates from Gambia [accession numbers AF350080
to AF350098] and 3 isolates from India [accession numbers
AF418676, AF418677, and AF418678]) had A1984 at the
RFLP site that would allow the amplicons to be digested by
BglII, a characteristic of HBV/Ae, but because they had T1809
or A1809/T1812, they would not be amplified by the HBV/Ae-
specific primers and therefore would not be classified as HBV/
Ae.
The application of this assay for HBV/A isolates from sera
obtained from paid donors from the United States and HBV
carriers from South Africa showed that the majority of HBV
isolates from African-Americans, Caucasians, and Hispanics in
the United States were HBV/Ae, whereas isolates from Asians
living in the United States and black South Africans were
mainly HBV/Aa (Fig. 5). Although almost all HBV/A isolates
from black Africans were classified as HBV/Aa, which was
consistent with previous reports (5, 13, 16), 84.2% of African-
Americans had HBV/Ae. This difference between the subtypes
in African-Americans and the Africans may be an indication
that the infection may be a consequence of the interaction of
African-Americans with other races in the United States as
opposed to the introduction of HBV from Africa during the
slavery period in the 19th century. However, further studies
with a larger number of African-Americans and more detailed
sequencing analysis would be necessary to support this assump-
tion. On the other hand, the high prevalence of HBV/Aa in the
Asian community in the United States may be a reflection of
the high rate of migration from Asia to the United States in
recent years.
Infection with HBV/Aa is associated with low prevalence of
HBeAg in serum and early seroconversion (14, 15). Recently
Ahn and coworkers showed that the T1809/T1812 mutations
interfere with the translation of HBeAg in vitro and may be
responsible for the early loss of HBeAg seen in southern Af-
rican black carriers of HBV (1). Because of the low frequency
of HBeAg positivity among the paid donors, however, we did
not find a significant difference between the prevalence of
HBeAg in carriers infected with the two different subtypes of
genotype A. A large scale case-control study would be neces-
sary in order to investigate this further.
In conclusion, we have described a novel HBV/A subtyping
FIG. 5. The prevalence of HBV/Ae and HBV/Aa among different
races from 109 U.S. paid donors (A) and 32 black African carriers
(B) determined using the HBV/A subtyping assay. The vertical axis
indicates percent frequency of HBV/A subtypes. The prevalence was
statistically significant between African-Americans and Asians, be-
tween Caucasians and Asians, and between Hispanics and Asians.
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assay that can differentiate between subtypes Aa and Ae. The
specificity and sensitivity of the HBV/A subtype-specific PCR
combined with a RFLP assay were confirmed, and the useful-
ness of this assay in a practical context was demonstrated. This
assay will contribute to further clinical or epidemiological stud-
ies that will allow us to clarify the differences between the two
subtypes Aa and Ae.
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